Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 13/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723500 | 0.86 | NTRK1 (0.42) | RETDPP4NTRK1MCHR1 | |
| SCHEMBL14730294 | 0.86 | NTRK1 (0.42) | RETDPP4NTRK1MCHR1 | |
| SCHEMBL14722263 | 0.85 | NTRK1 (0.43) | RETDPP4NTRK1MCHR1 | |
| SCHEMBL14730278 | 0.85 | NTRK1 (0.43) | RETDPP4NTRK1MCHR1 | |
| SCHEMBL609161 | 0.84 | AAK1 (0.41) | RETDPP4NTRK1 | |
| SCHEMBL1720753 | 0.83 | NTRK1 (0.40) | RETNTRK1MCHR1 | |
| SCHEMBL609468 | 0.83 | NTRK1 (0.40) | RETNTRK1MCHR1 | |
| SCHEMBL10058396 | 0.83 | NTRK1 (0.40) | RETDPP4NTRK1MCHR1 | |
| SCHEMBL14730297 | 0.83 | NTRK1 (0.43) | RETDPP4NTRK1MCHR1 | |
| SCHEMBL14723371 | 0.83 | NTRK1 (0.43) | RETDPP4NTRK1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | RET 1439/4885DPP4 217/4885NTRK1 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.